首页> 外文OA文献 >MP22-07 INDIRECT COMPARISON OF SURVIVAL AND COST PER NUMBER NEEDED TO TREAT TO BENEFIT ANALYSIS OF ABIRATERONE, ENZALUTAMIDE, AND SIPULEUCEL-T IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

【2h】

MP22-07 INDIRECT COMPARISON OF SURVIVAL AND COST PER NUMBER NEEDED TO TREAT TO BENEFIT ANALYSIS OF ABIRATERONE, ENZALUTAMIDE, AND SIPULEUCEL-T IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

机译：在治疗转移阉割前列腺癌的治疗中，治疗血液酮，依甲酰胺和西普尔-T的效益分析所需的存活率和成本间接比较。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Scott C. Flanders; Ben H. Lowentritt; Jason M. Hafron; Bruce A. Brown; David S. Morris*;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis [J] . Schultz Neil M., Flanders Scott C., Wilson Samuel, Advances in therapy. . 2018,第10期

机译：治疗持续时间，医疗资源利用率和化疗 - 天真患者的转移性阉割前列腺癌患者的成本，用乙醛胺或醋酸盐酸酯治疗：回顾性要求分析
2. NUMBER NEEDED TO TREAT AND ASSOCIATED INCREMENTAL COSTS OF TREATMENT WITH ENZALUTAMIDE VERSUS ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SPAIN AND THE UNITED KINGDOM [J] . Duran A., Watt M., Flanders S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：治疗和相关的烯醇胺治疗的醋酸盐和血液治疗中的化疗 - 幼稚患者的抗泼尼松治疗的数量，在西班牙和英国的转移阉割前列腺癌中
3. NUMBER NEEDED TO TREAT AND ASSOCIATED INCREMENTAL COSTS OF TREATMENT WITH ENZALUTAMIDE VERSUS ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN SPAIN AND THE UNITED KINGDOM [J] . Duran A., Watt M., Flanders S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：治疗和相关的烯醇胺治疗的醋酸盐和血液治疗中的化疗 - 幼稚患者的抗泼尼松治疗的数量，在西班牙和英国的转移阉割前列腺癌中
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. The Impact of Heterogeneity of Treatment Effect on Survival, Cost Effectiveness, and Coverage of Androgen Deprivation Therapy in Metastatic Prostate Cancer [D] . Aly, Abdalla 2015

机译：异质性对转移性前列腺癌生存率，成本效益和雄激素剥夺疗法覆盖率的影响
6. Treatment Duration Healthcare Resource Utilization and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis [O] . Neil M. Schultz, Scott C. Flanders, Samuel Wilson, -1

机译：恩扎鲁胺或醋酸阿比特龙治疗的初治转移性去势抵抗性前列腺癌患者的治疗持续时间医疗资源利用和费用：回顾性索赔分析
7. Abiraterone and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post Chemotherapy: An Indirect Comparison and Budget Impact Analysis [O] . T. Li, M. Thompson, M. Todd, 2013

机译：AbiraTerone和苯甲丁酰胺用于治疗转移性阉割前列腺癌（MCRPC）后化疗：间接比较和预算影响分析

MP22-07 INDIRECT COMPARISON OF SURVIVAL AND COST PER NUMBER NEEDED TO TREAT TO BENEFIT ANALYSIS OF ABIRATERONE, ENZALUTAMIDE, AND SIPULEUCEL-T IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

著录项

引文网络

相似文献

相关主题

期刊订阅